JP2020523319A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523319A5
JP2020523319A5 JP2019567691A JP2019567691A JP2020523319A5 JP 2020523319 A5 JP2020523319 A5 JP 2020523319A5 JP 2019567691 A JP2019567691 A JP 2019567691A JP 2019567691 A JP2019567691 A JP 2019567691A JP 2020523319 A5 JP2020523319 A5 JP 2020523319A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/036554 external-priority patent/WO2018227018A1/en
Publication of JP2020523319A publication Critical patent/JP2020523319A/ja
Publication of JP2020523319A5 publication Critical patent/JP2020523319A5/ja
Pending legal-status Critical Current

Links

JP2019567691A 2017-06-07 2018-06-07 免疫調節化合物の抗体コンジュゲートおよびその使用 Pending JP2020523319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516638P 2017-06-07 2017-06-07
US62/516,638 2017-06-07
PCT/US2018/036554 WO2018227018A1 (en) 2017-06-07 2018-06-07 Antibody conjugates of immune-modulatory compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2020523319A JP2020523319A (ja) 2020-08-06
JP2020523319A5 true JP2020523319A5 (cg-RX-API-DMAC10.html) 2021-07-26

Family

ID=64567206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567691A Pending JP2020523319A (ja) 2017-06-07 2018-06-07 免疫調節化合物の抗体コンジュゲートおよびその使用

Country Status (7)

Country Link
US (1) US20200199247A1 (cg-RX-API-DMAC10.html)
EP (1) EP3634485A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020523319A (cg-RX-API-DMAC10.html)
CN (1) CN110891605A (cg-RX-API-DMAC10.html)
AU (1) AU2018279105A1 (cg-RX-API-DMAC10.html)
CA (1) CA3065852A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018227018A1 (cg-RX-API-DMAC10.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
BR112020023926A2 (pt) * 2018-05-25 2021-02-17 Silverback Therapeutics, Inc. compostos de amino-pirazinocarboxamida, conjugados e usos dos mesmos
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CA3139274A1 (en) * 2019-05-10 2020-11-19 Lyvgen Biopharma Co., Ltd. Humanized anti-cd137 antibodies and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP3999544A4 (en) * 2019-07-19 2023-08-09 Wuxi Xdc Singapore Private Limited POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
WO2021102332A1 (en) * 2019-11-22 2021-05-27 Silverback Therapeutics, Inc. Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof
EP4041769A1 (en) * 2019-12-12 2022-08-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Antibody-drug conjugates specific for cd276 and uses thereof
CN115052663B (zh) * 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
TWI854088B (zh) * 2020-01-27 2024-09-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αvβ8整聯蛋白抗體
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN115379848A (zh) * 2020-04-01 2022-11-22 加利福尼亚大学董事会 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂
CN113509557A (zh) * 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
WO2021231922A1 (en) * 2020-05-14 2021-11-18 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
WO2021243136A2 (en) * 2020-05-29 2021-12-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods and compositions for treating, preventing the onset and/or slowing progression of osteoarthritis
EP4157883A4 (en) * 2020-06-02 2024-12-04 Children's Medical Center Corporation NANOBODY CONJUGATES (VHH) AND THEIR USES
CN117083079A (zh) * 2020-06-02 2023-11-17 儿童医学中心公司 纳米抗体(vhh)缀合物及其用途
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
KR102506295B1 (ko) * 2020-08-28 2023-03-08 국립암센터 디그옥시제닌에 대한 인간화 항체 및 이의 용도
CN114146095A (zh) * 2020-09-07 2022-03-08 是光隽恒(北京)生物科技有限公司 用于组织损伤修复的组合物及其制备方法和用途
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
GB202104935D0 (en) * 2021-04-07 2021-05-19 Hummingbird Bioscience Holdings Pte Ltd BCMA/TACI antigen-binding molecules
WO2022109105A1 (en) * 2020-11-18 2022-05-27 Pandion Operations, Inc. Madcam targeted therapeutics and uses thereof
AU2022254042A1 (en) * 2021-04-07 2023-09-14 Mythic Therapeutics, Inc. Antigen-binding protein constructs and antibodies and uses thereof
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
JP2024526259A (ja) 2021-07-02 2024-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗protac抗体および複合体
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US20250043005A1 (en) * 2021-12-09 2025-02-06 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-cytokine fusion proteins and applications thereof
EP4458830A4 (en) * 2021-12-30 2025-12-03 Sichuan Kelun Biotech Biopharmaceutical Co Ltd TRICYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS USE
CA3262796A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific Polypeptides and Their Uses
CN120417934A (zh) * 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
IL321713A (en) 2022-12-27 2025-08-01 Merck Patent Gmbh Anti-PROTAC VHH antibodies and complexes
WO2024200987A1 (en) * 2023-03-31 2024-10-03 Avacta Life Sciences Limited Tnfr2 binding polypeptides and methods of use
FR3147278A1 (fr) * 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
FR3147292A1 (fr) * 2023-03-31 2024-10-04 Affyxell Therapeutics Co., Ltd. Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
KR20260023524A (ko) * 2023-05-18 2026-02-20 파이어플라이 바이오, 인크. 이소인돌리논-글루타르이미드 항체 접합체 및 이의 용도
WO2024243545A1 (en) * 2023-05-24 2024-11-28 President And Fellows Of Harvard College Compositions targeting endothelial cells and uses thereof
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
TW202547866A (zh) 2024-01-10 2025-12-16 丹麥商珍美寶股份有限公司 Slitrk6結合劑、其共軛物及使用彼之方法
WO2025163120A1 (en) * 2024-02-01 2025-08-07 Adcytherix Sas ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
EP4595981A1 (en) * 2024-02-01 2025-08-06 Jack Elands Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025216667A1 (en) * 2024-04-12 2025-10-16 Joint Stock Company «Biocad» Monoclonal antibody that specifically binds to bdca-2
WO2026093513A1 (en) 2024-10-31 2026-05-07 Sotio Biotech A.S. Anti-lrrc15 antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
KR101281501B1 (ko) * 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
WO2011040973A2 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
WO2011040972A1 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
CN104053513B (zh) * 2012-01-26 2016-05-11 株式会社万 弯曲中空管的制造方法
DK3151865T3 (da) * 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
EP3383909B1 (en) * 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
JP2019501124A (ja) * 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗huLRRC15抗体薬物コンジュゲート及びその使用方法
US20210154188A1 (en) * 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
BR112020023926A2 (pt) * 2018-05-25 2021-02-17 Silverback Therapeutics, Inc. compostos de amino-pirazinocarboxamida, conjugados e usos dos mesmos

Similar Documents

Publication Publication Date Title
US20250346661A1 (en) Dual specific antibodies
JP2019530434A5 (cg-RX-API-DMAC10.html)
FI3625259T3 (fi) Anti-sirp-alfa vasta-aineet
EP3470424B1 (en) Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
JP2021524267A5 (cg-RX-API-DMAC10.html)
KR20220024729A (ko) B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법
JP2021508469A5 (cg-RX-API-DMAC10.html)
JP2019502712A5 (cg-RX-API-DMAC10.html)
JP2020528768A5 (cg-RX-API-DMAC10.html)
JP2010517513A5 (cg-RX-API-DMAC10.html)
JP2015500207A5 (cg-RX-API-DMAC10.html)
CN112469477A (zh) 与成纤维细胞活化蛋白结合的异源二聚体抗体
JP2018517401A5 (cg-RX-API-DMAC10.html)
RU2021129189A (ru) Антитела против фактора свертывания xi
JP2014520088A5 (cg-RX-API-DMAC10.html)
JP2014531201A5 (cg-RX-API-DMAC10.html)
JP2025183307A5 (cg-RX-API-DMAC10.html)
JP2022545741A5 (cg-RX-API-DMAC10.html)
JP2021525059A5 (cg-RX-API-DMAC10.html)
CA3140075A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
JP2019537617A5 (cg-RX-API-DMAC10.html)
CN110267990A (zh) 结合共刺激性和检查点受体的双特异性免疫调节抗体
JP2013521252A5 (cg-RX-API-DMAC10.html)
JP2019528046A5 (cg-RX-API-DMAC10.html)
JP2023076596A5 (cg-RX-API-DMAC10.html)